§ feed · storyline
Isomorphic Labs raises $2.1 billion for AI drug discovery
Isomorphic Labs raises $2.1 billion in a Series B round led by Thrive Capital to expand its IsoDDE platform and advance AI-discovered drug candidates toward clinical trials.
Isomorphic Labs, the AI drug research company led by DeepMind co-founder Demis Hassabis, has closed a $2.1 billion Series B round led by Thrive Capital. The funding will go toward expanding its in-house platform IsoDDE and advancing drug candidates toward clinical trials.
The article Alphabet's Isomorphic Labs raises $2.1 billion to scale AI drug discovery toward clinical trials appeared first on The Decoder.
§ sources1 publication · timeline below